Solid Tumors
Augtyro Approved for Adult and Pediatric Patients With NTRK Gene Fusion-Positive Solid Tumors
The FDA has granted accelerated approval to Augtyro for adult and pediatric patients 12 years of age and older with ...
JUNE 17, 2024
Retevmo Approved for Pediatric Patients with RET-altered Metastatic Thyroid Cancer or Solid Tumors
The FDA has granted accelerated approval to Retevmo for pediatric patients two years of age and older for several ...
MAY 30, 2024
Subcutaneous Injection of Nivolumab on the Horizon
Patients and clinicians may have an injectable form of the immunotherapy Opdivo available in their future.
MAY 13, 2024
FDA Approves First Interchangeable Biosimilars to Xgeva and Prolia
The FDA approved the first interchangeable biosimilar to Prolia and Xgeva.
MARCH 7, 2024
FDA Expands Pediatric Indication for Rozlytrek and Approves New Pellet Formulation
The FDA granted accelerated approval to entrectinib (Rozlytrek, Genentech) for pediatric patients older than 1 ...
OCTOBER 26, 2023
Keytruda Granted Full Approval for MSI-H/dMMR Solid Tumors
The FDA granted full approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients ...
APRIL 5, 2023
FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-positive Solid Tumors
The FDA has granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult patients with ...
SEPTEMBER 29, 2022
100% Remission Rate ‘Thrills’ Rectal Cancer Investigators
A phase 2 study of patients with early-stage rectal cancer, conducted at Memorial Sloan Kettering Cancer ...
JUNE 8, 2022
FDA Approves Vitrakvi for Solid Tumors With NTRK Gene Fusions
Larotrectinib is indicated for tumors that have a NTRK gene fusion without a known acquired resistance mutation, ...
NOVEMBER 28, 2018
